EN DE
Watch Daiichi Sankyo Co Ltd ADR for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Daiichi Sankyo Co Ltd (DSNKY) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Daiichi Sankyo Co Ltd stock $7.99, price $17.86, that is 55.3% below the price, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ADR · Home Japan

DS Daiichi Sankyo Co Ltd logo Broad data Nov 6, 2026

Daiichi Sankyo Co Ltd

DSNKY · US
Very expensive, in a downtrend

Our calculation puts a fair price 55% below what the stock costs today.

Solidly profitable · 10.9% net margin (TTM)
Low debt
Broad data
Revenue last quarter +21% vs. a year ago.
Quality 54/100
Expensive Growth (revenue 5y +18.5 %/yr in JPY)
2.8% dividend yield · Watch coverage
Mixed vs. peers (6/14)
Moderate moat 63/100
Fair value $7.99 · Strongly overvalued (−55.3%)
Negative free cash flow
Downbeat coverage

Risks from the AI analysis

🚩Withdrawal of small-cell lung cancer ADC application due to insufficient data🚩Chinese ADC biotechs intensify rivalry🚩Enhertu patent expiry from 2033🚩DXd platform faces repeated regulatory hurdles
Watch Daiichi Sankyo Co Ltd ADR for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$39.83 $14.68 Fair Value $7.99 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $14.68 – $39.83 · fair‑value band $6.15 – $11.60 · the $17.86 price screens above the $7.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Daiichi Sankyo Co Ltd ADR in your weekly email

Every Wednesday you see whether Daiichi Sankyo Co Ltd ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.

Show moreShow less

The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.

In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication.

Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections.

It has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research; Daiichi Sankyo Company, Limited has a strategic collaboration with Leica Biosystems and AstraZeneca to develop an immunohi

Stock analysis

Daiichi Sankyo Co Ltd (DSNKY) currently trades at $17.86, while our model-based Fair Value estimate is $7.99, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $18.81 per share, and 4 of the 17 models we run sit above the $17.86 price.

Bear case: the Asset-Based group reads lowest at $3.09, and 13 of the 17 models stay below the price. Data coverage for this calculation is high.

Scenario range: $6.15 (bear) to $11.60 (bull), the price of $17.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Daiichi Sankyo Co Ltd ADR reported revenue of ¥2.3T in FY2026 versus ¥1.0T in FY2022, a compound +21.2%/yr. Reported net income was ¥276B in FY2026, compounding +42.4%/yr from FY2022.

Key figures

Market cap $32.5B Large · P/E ratio 20.8 · P/S ratio 2.54 · EPS (TTM) $0.8600 · Dividend yield 2.8% · Net margin 12.2% · Return on equity 14.8% · Return on assets (EBIT) 5.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (medium confidence).

What moves the price

The share trades about 25% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −55%, DSNKY screens richer than that median.

Fair Value models

Bear $6.15 Fair Value $7.99 Bull $11.60
Price $17.86 · Downside -55.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.2236 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $4.14 $6.17 $9.25 76
Residual Income $6.13 $7.80 $11.56 75
EPV $6.92 $7.96 $8.86 74
All 17 models by family
DCF Models
Owner Earnings $4.14 $6.17 $9.25 76
Earnings-Based
Graham-Dodd $6.50 $21.08 $28.15 64
Lynch FV $4.70 $6.72 $8.74 61
PEG = 1.0 $4.70 $6.72 $8.74 57
EPV $6.92 $7.96 $8.86 74
Dividend Discount
Gordon GGM $4.25 $8.66 $13.42 66
DDM Multi-Stage $4.25 $7.10 $9.11 66
Multiples
P/E Multiple $15.77 $21.03 $26.29 63
P/S Multiple $12.19 $16.25 $20.31 58
P/B Multiple $15.59 $20.78 $25.98 55
EV/EBIT $10.24 $13.48 $16.72 66
EV/EBITDA $11.52 $15.18 $18.85 67
EV/Revenue $7.46 $10.43 $13.41 54
Asset-Based
NCAV (Graham) $2.31 $3.09 $4.62 54
Economic Profit
Residual Income $6.13 $7.80 $11.56 75
ROIC Compounder $7.20 $9.00 $11.24 72
Growth Earnings
Growth-Adj P/E $13.16 $18.81 $24.45 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 55
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 56
Does it invest with discipline instead of growing at any price?
Low Volatility 74
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 25
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
Start year 2021 (pandemic). Over 10 years: +8.6% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+28.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.0%
Dividend (yield on the price)2.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.31.1% vs 14.3%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 10%
Pace: the 5-year rate starts in 2021 (pandemic)

DSNKY screens overvalued: fair value 55% below the price. Compare with Eli Lilly and Company →

Recent news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.
Note from the team Oct 11, 2026
AI conclusion: Decent margins and ROE support a moderate pharma moat while negative free cash flow and limited intangibles signals restrict durability.
Main risk: Hundreds of Chinese ADC developers with similar targets and DXd-like approaches could capture market share in oncology or pressure prices on Daiichi's Enhertu and Datroway.
Daiichi Sankyo is pushing its Datroway ADC forward through a fresh collaboration to test it with ivonescimab in several tumor types, beginning with a phase 3 study in first-line triple-negative breast cancer. Yet it also just withdrew the biologics license application for another ADC candidate in small-cell lung cancer because the supporting data fell short. Our models see the stock as overvalued. Can its DXd platform generate enough approved products to overcome repeated regulatory hurdles?
Join the discussion →

Compare Daiichi Sankyo Co Ltd ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside −55.3% · Bottom 25%
Profitability
Return on equity (12 months) 14.8% · Above median
Return on assets 6.9% · Below median
Net margin (12 months) 10.9% · Above median
Operating margin (12 months) 14.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 21.1% · Top 25%
Dividend yield (12 months) 2.8% · Above median
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 20.8× · Cheaper than median
P/B 3.08× · Pricier than median
P/S (12 months) 2.32× · Cheaper than median
EV/EBITDA 16.1× · Pricier than median
PEG 1.96× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)100 · sector 34
PAST (return on equity)59 · sector 41
HEALTH (low debt)91 · sector 93
DIVIDEND (yield)55 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $62.14 $75.91 +22% vs DSNKY
Gilead Sciences, Inc GILD $166.89 $183.58 +10% vs DSNKY
Amgen Inc AMGN $460.42 $506.31 +10% vs DSNKY
Novartis AG NOVN CHF 133.08 CHF 120.24 −10% vs DSNKY
AbbVie Inc ABBV $291.31 $259.62 −11% vs DSNKY
Merck & Co MRK $146.73 $129.26 −12% vs DSNKY
Pfizer Inc PFE $29.39 $24.87 −15% vs DSNKY
Roche Holding RO CHF 400.00 CHF 326.56 −18% vs DSNKY
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs DSNKY
Eli Lilly and Company LLY $1,354 $749.92 −45% vs DSNKY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Daiichi Sankyo Co Ltd ADR: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Daiichi Sankyo Co Ltd ADR Fair Value". https://www.fairvalue-calculator.com/stock/DSNKY

Frequently asked questions

Is Daiichi Sankyo Co Ltd (DSNKY) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $7.99 versus a price of $17.86, about 55% lower (overvalued).
What is the fair value of DSNKY?
Our model-based fair value for Daiichi Sankyo Co Ltd is $7.99 (as of Nov 6, 2026), built from audited fundamentals. The current price: $17.86.
What is the quality score of DSNKY?
Daiichi Sankyo Co Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daiichi Sankyo Co Ltd (DSNKY)?
Our model-based price target is the fair value of $7.99 (as of Nov 6, 2026) from 17 valuation models. Cautious scenario $6.15, optimistic scenario $11.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Daiichi Sankyo Co Ltd ADR stock forecast for 2026?
Our models put fair value at $7.99, about 55% lower versus a price of $17.86 (overvalued). Cautious scenario $6.15, optimistic scenario $11.60. The calculation is refreshed regularly with new filings.
What is the revenue of Daiichi Sankyo Co Ltd (DSNKY)?
Daiichi Sankyo Co Ltd reported trailing-twelve-month revenue of about ¥2.2T (latest available figure, as of Nov 6, 2026).
Does Daiichi Sankyo Co Ltd ADR pay a dividend?
Daiichi Sankyo Co Ltd currently shows a dividend yield of 2.76% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Daiichi Sankyo Co Ltd (DSNKY) and when is the ex-dividend date?
Daiichi Sankyo Co Ltd pays a dividend of $0.492 per share a year, a dividend yield of 2.8%. The last ex-dividend date was Mar 31, 2026. A dividend has been paid every year since at least 2009. The payout ratio is 51.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Daiichi Sankyo Co Ltd (DSNKY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daiichi Sankyo Co Ltd it is $7.99 per share (as of Nov 6, 2026), against a price of $17.86. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Daiichi Sankyo Co Ltd ADR stock overvalued or undervalued in 2026?
As of Nov 6, 2026, DSNKY trades above its calculated fair value: price $17.86, fair value $7.99, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DSNKY?
No. The price is what the market pays today ($17.86); the fair value is what the company's own numbers justify ($7.99). For Daiichi Sankyo Co Ltd the two are $9.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Daiichi Sankyo Co Ltd ADR worth?
The market values Daiichi Sankyo Co Ltd at about $32.5B (market capitalisation, as of Nov 6, 2026). Per share that is $17.86; our models calculate a fair value of $7.99 per share.
What do the bullish and bearish scenarios say about DSNKY?
Our models span a range for Daiichi Sankyo Co Ltd: cautious scenario $6.15, base $7.99, optimistic $11.60 per share (as of Nov 6, 2026, price $17.86). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DSNKY?
Daiichi Sankyo Co Ltd trades at a price-to-earnings ratio of 20.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.99 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2021 to 2026), reported earnings: 61.5. Other multiples: PEG 2.0, P/B 3.1, P/S 2.3, EV/EBITDA 16.1.
What is the PEG ratio of DSNKY?
The PEG ratio of Daiichi Sankyo Co Ltd is 1.96 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Daiichi Sankyo Co Ltd (DSNKY)?
Balance-sheet figures for Daiichi Sankyo Co Ltd (as of Nov 6, 2026): return on equity 14.8%, debt of 0.18 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is DSNKY from its 52-week high?
Daiichi Sankyo Co Ltd trades at $17.86, about 25% below its 52-week high of $23.91 and 22% above the low of $14.68 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.99 is for.
Which stocks are comparable to Daiichi Sankyo Co Ltd ADR?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daiichi Sankyo Co Ltd ADR stock attractive at the current price?
The data as of Nov 6, 2026: price $17.86, calculated fair value $7.99 (−55%), Quality Score 54/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DSNKY calculated?
We run Daiichi Sankyo Co Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.99 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Daiichi Sankyo Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daiichi Sankyo Co Ltd (DSNKY)?
The closing price on Nov 6, 2026 was $17.86. Our model-based fair value is $7.99, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daiichi Sankyo Co Ltd ADR right now?
The price sits above even our optimistic bull case ($11.60). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($6.15 to $11.60) leaves room in how you read the outcome.
Where does the earnings growth of Daiichi Sankyo Co Ltd (DSNKY) come from?
Earnings per share at Daiichi Sankyo Co Ltd grew +7.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.2 %, EBIT margin +2.9 %, tax rate +1.2 %, residual (interest, one-offs) −5.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Daiichi Sankyo Co Ltd

How large is the market capitalisation of Daiichi Sankyo Co Ltd (DSNKY)?
The market capitalisation of Daiichi Sankyo Co Ltd is $32.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daiichi Sankyo Co Ltd (DSNKY)?
The price-to-sales ratio of Daiichi Sankyo Co Ltd is 2.54 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daiichi Sankyo Co Ltd (DSNKY)?
Earnings per share at Daiichi Sankyo Co Ltd are $0.8600 (price ÷ EPS = P/E 20.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daiichi Sankyo Co Ltd (DSNKY)?
The dividend yield of Daiichi Sankyo Co Ltd is 2.8% (payout 57.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daiichi Sankyo Co Ltd (DSNKY)?
The net margin of Daiichi Sankyo Co Ltd is 12.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daiichi Sankyo Co Ltd (DSNKY)?
The return on equity (ROE) of Daiichi Sankyo Co Ltd is 14.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daiichi Sankyo Co Ltd (DSNKY)?
On an EBIT basis the return on assets of Daiichi Sankyo Co Ltd is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daiichi Sankyo Co Ltd (DSNKY)?
The operating margin of Daiichi Sankyo Co Ltd is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daiichi Sankyo Co Ltd (DSNKY)?
Revenue at Daiichi Sankyo Co Ltd is growing +21.1% versus a year earlier (3y avg +20.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daiichi Sankyo Co Ltd (DSNKY)?
Earnings per share at Daiichi Sankyo Co Ltd are growing −18.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daiichi Sankyo Co Ltd (DSNKY) generate?
The free cash flow of Daiichi Sankyo Co Ltd is −¥53.8B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Daiichi Sankyo Co Ltd (DSNKY) hold?
Daiichi Sankyo Co Ltd holds more cash than debt, ¥150B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Daiichi Sankyo Co Ltd ADR in the live analysis

One click puts Daiichi Sankyo Co Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.